New Treatment Stops Peyronie’s in 80% of Early Cases

By VirentaNews Staff — May 15, 2026

In a quiet urology clinic outside Boston, a 45-year-old man hesitates before speaking. His hands tremble slightly as he describes the invisible burden he’s carried for months: a growing curve in his penis, pain during erections, and the slow erosion of intimacy with his partner. Like millions of men with Peyronie’s disease, he felt isolated, ashamed, and out of options—until now. A new clinical study is offering a glimmer of hope where none existed before. For the first time, researchers have demonstrated that an early, non-invasive drug combination—using two widely available medications—can stop the progression of this debilitating condition and, in some cases, reverse early symptoms. The treatment, surprisingly simple, involves daily use of sildenafil, better known as Viagra, paired with a topical corticosteroid cream applied directly to the affected area. This dual approach targets both the fibrous plaque formation and the underlying vascular dysfunction that define Peyronie’s disease in its earliest stages.

Early Intervention Shows Promising Results

A recent trial published in The Journal of Sexual Medicine followed 78 men diagnosed with early-stage Peyronie’s disease over a 12-week period. Participants were instructed to take 50 mg of sildenafil daily and apply a 0.05% clobetasol propionate cream to the penile plaque twice a day. By the end of the study, 81% of patients showed no further progression of penile curvature, and 44% reported measurable improvement in both pain and plaque size. Erectile function, assessed using the International Index of Erectile Function (IIEF) questionnaire, improved significantly in 63% of participants. These results mark a turning point: until now, treatment options for early Peyronie’s disease were limited to observation, ineffective oral supplements, or eventual surgical correction. The study’s lead author, Dr. Michael Lee of Massachusetts General Hospital, emphasized the importance of timing: “The key is early diagnosis. Once the plaque matures and calcifies, medical therapy becomes far less effective. But in the acute inflammatory phase, we may have a window to intervene—and this combination appears to exploit it.”

The Long Road to Recognition

Peyronie’s disease, characterized by the development of fibrous scar tissue inside the penis, has been documented since the 18th century, yet it has long been shrouded in silence and stigma. Named after French surgeon François Gigot de la Peyronie, who first described it in 1743, the condition affects an estimated 3% to 9% of men, though the true prevalence is likely higher due to underreporting. For decades, the medical community treated it as a surgical problem, with interventions like penile implants or plaque incision reserved for advanced cases. Early-stage therapies—ranging from vitamin E to tamoxifen—failed to demonstrate consistent efficacy in clinical trials. As late as 2020, guidelines from the American Urological Association concluded that no pharmacological treatment could be recommended with confidence for early disease. The shift began with a deeper understanding of Peyronie’s as an inflammatory disorder with vascular components, not merely a structural issue. This paradigm change opened the door to exploring drugs that improve blood flow and reduce fibrosis—like sildenafil and corticosteroids—working in tandem.

The Doctors Challenging the Status Quo

At the forefront of this emerging treatment strategy are urologists like Dr. Lee and Dr. Sarah Chen at the University of California, San Francisco, who have long advocated for early medical intervention. Their motivation stems from seeing patients delay care for years, often until deformity or erectile dysfunction becomes irreversible. “Men don’t talk about this,” Dr. Chen said in an interview. “They feel embarrassed, or they think it’s just part of aging. By the time they come in, surgery is their only real option.” The new protocol is part of a broader push to destigmatize male sexual health and integrate Peyronie’s screening into routine men’s health exams. Pharmaceutical companies have shown little interest in developing new drugs for the condition due to its relatively small market size, so clinicians are repurposing existing medications—a low-cost, high-impact approach. The research team is now planning a larger, multicenter trial to confirm their findings and potentially influence future treatment guidelines.

Implications for Patients and Providers

If validated, this dual-drug strategy could transform the standard of care for early Peyronie’s disease. Millions of men worldwide could avoid surgery, preserve sexual function, and maintain psychological well-being. Primary care physicians and urologists may need to adopt more proactive screening, asking targeted questions during routine visits. The treatment’s affordability—sildenafil is generic and clobetasol cream is widely available—makes it accessible across healthcare systems. However, caution remains: corticosteroids can thin penile skin if misused, and long-term safety data are still lacking. The protocol is not recommended for men with diabetes or compromised skin integrity. Still, patient advocacy groups like the Peyronie’s Disease Society have welcomed the findings as a long-overdue breakthrough.

The Bigger Picture

This study reflects a growing trend in medicine: reimagining existing drugs for new purposes, especially in under-researched areas. Conditions that affect male sexual health—often sidelined due to stigma—stand to benefit from renewed scientific attention. The success of repurposing sildenafil, originally developed for angina, now used for erectile dysfunction and pulmonary hypertension, underscores the value of exploring secondary indications. In doing so, medicine not only treats disease but also restores dignity.

What comes next is both clinical and cultural. Larger trials will determine how widely this therapy can be adopted, while public health efforts must address the silence surrounding Peyronie’s disease. For the man in the Boston clinic, the treatment brought more than physical relief—it restored a sense of hope. As research advances, the medical community has a chance to redefine how it treats not just a condition, but the men who live with it.

Source: MedicalXpress